Vipin K. Garg is President and Chief Executive Officer at Altimmune.
Dr. Garg has served as president and chief executive officer (CEO) for Altimmune since November 2018.
He has more than three decades of experience in the biotechnology and pharmaceutical industries with a successful track record of building and leading private and publicly traded companies.
Prior to joining Altimmune, he served as president and CEO of Neos Therapeutics (Nasdaq: NEOS), where he built a commercial-stage biopharmaceutical company and launched several branded therapeutic products. He served as president and CEO of Tranzyme Pharma (Nasdaq: TZYM), prior to Neos, where he progressed the company from a discovery-stage, emerging biotech to a Nasdaq-listed clinical-stage, drug development company.
Prior to that, Dr. Garg served as CEO of Apex Bioscience, Inc. (acquired by Curacyte AGof Munich, Germany). He has held senior management positions at DNX Bio-Therapeutics, Inc., until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Sumitomo Dainippon Pharma), and Bio-Response Inc. (acquired by Baxter Healthcare Corporation).
Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia, and his M.S. from IARI Nuclear Research Laboratory, New Delhi, India in 1978.